FDA Approval of Tradipitant: A Novel Approach to Motion Sickness Treatment

Authors

• Haley BrownFollow
• Jennifer CaoFollow
• Allie HonigfordFollow
• Leah HeitkampFollow
• Sarah HiettFollow
• Connor DainsFollow
• Brenna HissongFollow
• Manoranjan D'SouzaFollow

Abstract

Motion sickness is a prevalent neurophysiological condition affecting approximately one-third of the worldwide population, resulting from sensory mismatch and the brain’s internal model of motion. It is characterized by nausea, vomiting, dizziness, and autonomic symptoms during exposure to actual or virtual motion, which may significantly impair daily functioning and quality of life. Current guidelines recommend the prevention and treatment of motion sickness through pharmacologic, herbal, and non-pharmacologic strategies. Scopolamine and first-generation antihistamines are effective pharmacologic options, while ginger has demonstrated some benefit in reducing symptoms as an herbal option. Non-pharmacologic interventions such as habituation training, behavioral techniques, and sensory strategies can further mitigate nausea and vomiting. These treatment options can help prevent or relieve motion sickness symptoms but are limited by side effects and incomplete efficacy, highlighting the need for new treatments. In December 2025, the United States Food and Drug Administration (FDA) approved tradipitant (Nereus^TM), making it the first new medication in 40 years indicated for the prevention of motion sickness. Tradipitant is a selective neurokinin-1 (NK-1) receptor antagonist that targets pathways implicated in the pathophysiology of nausea and vomiting. Two phase three studies, Motion Syros and Motion Serifos, have demonstrated the safety and efficacy of tradipitant in the prevention of motion sickness.